ESC Premium Access

Efficacy and safety of oral anticoagulant versus antiplatelet therapy for secondary prevention of cardiovascular disease in patients without atrial fibrillation

Congress Session

About the speaker

Doctor Fabrizio Ricci

G. d Annunzio University of Chieti-Pescara, Chieti (Italy)
1 presentation
0 follower

4 more presentations in this session

A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction: the ALTIC-2 study

Speaker: Doctor I. Lianos (Athens, GR)

Thumbnail

Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis

Speaker: Doctor D. Errigo (Turin, IT)

Thumbnail

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischaemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients

Speaker: Doctor J. Li (Beijing, CN)

Thumbnail

Bleedings during antithrombotic therapy: a blessing in disguise

Speaker: Doctor D. Cosmi (Perugia, IT)

Thumbnail

Access the full session

Poster Session 3 - Antiplatelet therapy

Speakers: Doctor F. Ricci, Doctor I. Lianos, Doctor D. Errigo, Doctor J. Li, Doctor D. Cosmi
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk